Finoriq research workspace
VERTEX PHARMACEUTICALS INC / MA (VRTX) SEC Filings & Filing Highlights
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States. Review VRTX SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
- Company
- VERTEX PHARMACEUTICALS INC / MA (VRTX)
- Ticker
- VRTX
- Market Cap
- $122.4B
- Latest Price
- $482.28
- Industry
- Biotech & Pharma
VERTEX PHARMACEUTICALS INC / MA (VRTX) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for VERTEX PHARMACEUTICALS INC / MA (VRTX).
| Event | Form | Date |
|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA: Shareholder voteThe Annual Meeting was held on May 13, 2026. Set forth below are the voting results for each of the proposals submitted to a vote of the Co... | 8-K5.07 | 2026-05-13 |
| On March 27, 2026, the Board of Directors (the "Board") of Vertex Pharmaceuticals Incorporated...On March 27, 2026, the Board of Directors (the "Board") of Vertex Pharmaceuticals Incorporated (the "Company") approved the Vertex Pharmace... | 8-K5.02 | 2026-05-13 |
| Vertex Reports First Quarter 2026 Financial ResultsVertex Reports First Quarter 2026 Financial Results | 8-K2.02 | 2026-05-04 |
| On April 28, 2026, Suketu Upadhyay informed the board of directors (the “Board”) of Vertex Phar...On April 28, 2026, Suketu Upadhyay informed the board of directors (the “Board”) of Vertex Pharmaceuticals Incorporated (the “Company”) of... | 8-K5.02 | 2026-04-29 |
| Special Note Regarding Forward-Looking StatementsVertex Pharmaceuticals Incorporated (the “Company”) has completed the submission to the U.S. Food and Drug Administration (the “FDA”) of it... | 8-K8.01 | 2026-03-31 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.